Clinical significance of MicoRNA-155 expression in human breast cancer

被引:85
作者
Chen, Jian [1 ,2 ]
Wang, Bing-Chan [3 ]
Tang, Jin-Hai [1 ,4 ]
机构
[1] Nanjing Univ Tradit Chinese Med, Affiliated Hosp 1, Dept Gen Surg, Nanjing, Jiangsu, Peoples R China
[2] First Peoples Hosp Kunshan, Dept Hepatobiliary Surg, Kunshan, Peoples R China
[3] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Gen Surg, Xian 710049, Peoples R China
[4] Jiangsu Prov Tumor Hosp, Dept Gen Surg, Nanjing 210009, Jiangsu, Peoples R China
关键词
microRNA-155; breast cancer; prognosis; disease-free survival; overall survival; radiosensitivity; MICRORNA-155; SURVIVAL; GROWTH;
D O I
10.1002/jso.22153
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The aim of this study is to investigate clinical significance of miR-155 expression in breast cancer. Methods TaqMan real-time RT-PCR was performed to detect miR-155 expression in breast cancer tissues. The correlation of miR-155 expression with clinicopathological factors and prognosis of breast cancer patients was analyzed. Then, the prognostic value of miR-155 expression was analyzed by univariate and multivariate analyses. Moreover, the effect of miR-155 expression on phenotypes of breast cancer cell was determined by antisense technology. Results The relative expression of miR-155 was significantly higher in breast cancer tissues than in corresponding nontumor tissues. High miR-155 expression was correlated with higher tumor grade, advanced tumor stage and lymph node metastasis (P?=?0.012, 0.001, and 0.003, respectively). KaplanMeier survival analysis indicated that the disease-free and overall survival rates of high miR-155 group were significantly lower than those of low miR-155 group (P?=?0.038 and 0.029, respectively). Multivariate analysis showed that high miR-155 expression was a poor prognostic factor (P?=?0.009). Furthermore, antisense targeting miR-155 could inhibit growth, induce cell arrest in G0/G1 phase, enhance apoptosis, and increase radiosensitivity in breast cancer cells. Conclusions MiR-155 expression might be an independent prognostic factor and a therapeutic target for human breast cancer. J. Surg. Oncol. 2012; 106:260266. (c) 2011 Wiley Periodicals, Inc.
引用
收藏
页码:260 / 266
页数:7
相关论文
共 31 条
  • [1] MicroRNA functions in animal development and human disease
    Alvarez-Garcia, I
    Miska, EA
    [J]. DEVELOPMENT, 2005, 132 (21): : 4653 - 4662
  • [2] [Anonymous], BREAST CANC RES TREA
  • [3] The impact of microRNAs on protein output
    Baek, Daehyun
    Villen, Judit
    Shin, Chanseok
    Camargo, Fernando D.
    Gygi, Steven P.
    Bartel, David P.
    [J]. NATURE, 2008, 455 (7209) : 64 - U38
  • [4] MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004)
    Bartel, David P.
    [J]. CELL, 2007, 131 (04) : 11 - 29
  • [5] Roles of small RNAs in tumor formation
    Di Leva, Gianpiero
    Croce, Carlo M.
    [J]. TRENDS IN MOLECULAR MEDICINE, 2010, 16 (06) : 257 - 267
  • [6] Upregulation of MiR-155 in Nasopharyngeal Carcinoma is Partly Driven by LMP1 and LMP2A and Downregulates a Negative Prognostic Marker JMJD1A
    Du, Zi-Ming
    Hu, Li-Fu
    Wang, Hai-Yun
    Yan, Li-Xu
    Zeng, Yi-Xin
    Shao, Jian-Yong
    Ernberg, Ingemar
    [J]. PLOS ONE, 2011, 6 (04):
  • [7] MicroRNAs and Metastasis: Little RNAs Go a Long Way
    Dykxhoorn, Derek M.
    [J]. CANCER RESEARCH, 2010, 70 (16) : 6401 - 6406
  • [8] Gotte M, 2010, Minerva Ginecol, V62, P559
  • [9] MicroRNA-155 Functions as an OncomiR in Breast Cancer by Targeting the Suppressor of Cytokine Signaling 1 Gene
    Jiang, Shuai
    Zhang, Hong-Wei
    Lu, Ming-Hua
    He, Xiao-Hong
    Li, Yong
    Gu, Hua
    Liu, Mo-Fang
    Wang, En-Duo
    [J]. CANCER RESEARCH, 2010, 70 (08) : 3119 - 3127
  • [10] The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells
    Kato, M.
    Paranjape, T.
    Ullrich, R.
    Nallur, S.
    Gillespie, E.
    Keane, K.
    Esquela-Kerscher, A.
    Weidhaas, J. B.
    Slack, F. J.
    [J]. ONCOGENE, 2009, 28 (25) : 2419 - 2424